# Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Source: https://onco.cc/trials/nct06580301/  
OnCo record `nct06580301` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of YK012 in acute lymphoblastic leukaemia, run by Excyte Biopharma Ltd, now recruiting.

## Summary

Study of YK012 in B-cell Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT06580301 by Excyte Biopharma Ltd, with 46 participants planned, started 2024-09-25 and due to reach its primary completion in 2026-12-31. Interventions recorded: YK012.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06580301
- Phase: 1/2
- Setting: An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YK012 in Participants With B-cell Acute Lymphoblastic Leukemia
- Sponsor: Excyte Biopharma Ltd
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06580301: https://clinicaltrials.gov/study/NCT06580301

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)

---
JSON: https://onco.cc/api/v1/entities/nct06580301.json